{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T15:15:38Z","timestamp":1794323738952,"version":"4.9.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T00:00:00Z","timestamp":1728864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T00:00:00Z","timestamp":1728864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    This research was intended to compare the clinical efficacy of hepatic arterial infusion chemotherapy (HAIC) in conjunction with lenvatinib and PD-1 inhibitors to first-line systemic chemotherapy for advanced intrahepatic cholangiocarcinoma(ICC). The research enrolled advanced ICC patients who underwent HAIC plus lenvatinib and PD-1 inhibitor(\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200951) or first-line systemic chemotherapy(cisplatin\u2009+\u2009gemcitabine,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200939) between July 2020 to January 2023 in Zhongshan People\u2019s Hospital.Their clinical outcomes were assessed through measurement of parameters encompassing objective response rate (ORR), disease control rate (DCR), median overall survival (mOS), median progression-free survival (mPFS), median duration of response (mDOR), and treatment-related adverse events (TRAEs). In accordance with the RECIST1.1, the ORR in the HAIC\u2009+\u2009L\u2009+\u2009P and SC groups was 43.1% and 20.5%, while the DCR was 90.2% and 69.2%, respectively (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.04 and =\u20090.02, respectively). The change in the maximum diameter of intrahepatic target lesions in patients before and after treatment and the diameter of intrahepatic tumors in the HAIC\u2009+\u2009L\u2009+\u2009P group were sharply smaller versus the SC group (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001). The HAIC\u2009+\u2009L\u2009+\u2009P group had prolonged mOS (16.8 months vs. 11.0 months,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.01) and mPFS (12.0 months vs. 6.9 months,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.01) in comparison with the SC group. Compared to first-line systemic chemotherapy(cisplatin\u2009+\u2009gemcitabine), HAIC plus lenvatinib and PD-1 inhibitors contributes to improvement of tumor response and prolongation of OS and PFS in advanced ICC patients.\n                  <\/jats:p>","DOI":"10.1038\/s41598-024-75102-z","type":"journal-article","created":{"date-parts":[[2024,10,13]],"date-time":"2024-10-13T21:01:44Z","timestamp":1728853304000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Efficacy analysis of HAIC combined with lenvatinib plus PD-1 inhibitor vs. first-line systemic chemotherapy for advanced intrahepatic cholangiocarcinoma"],"prefix":"10.1038","volume":"14","author":[{"given":"Zhipeng","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xugong","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dabei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,14]]},"reference":[{"key":"75102_CR1","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1002\/cncr.32803","volume":"126","author":"AA Florio","year":"2020","unstructured":"Florio, A. A. et al. Global trends in intrahepatic and extrahepatic cholangiocarcinoma incidence from 1993 to 2012. Cancer. 126, 2666\u20132678 (2020).","journal-title":"Cancer"},{"key":"75102_CR2","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/nrclinonc.2017.157","volume":"15","author":"S Rizvi","year":"2018","unstructured":"Rizvi, S., Khan, S. A., Hallemeier, C. L., Kelley, R. K. & Gores, G. J. Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nat. Rev. Clin. Oncol. 15, 95\u2013111 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"75102_CR3","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","volume":"17","author":"JM Banales","year":"2020","unstructured":"Banales, J. M. et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat. Rev. Gastroenterol. Hepatol. 17, 557\u2013588 (2020).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"75102_CR4","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle, J. et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl. J. Med. 362, 1273\u20131281 (2010).","journal-title":"N Engl. J. Med."},{"key":"75102_CR5","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1002\/cam4.299","volume":"3","author":"F Fiteni","year":"2014","unstructured":"Fiteni, F. et al. Cisplatin\/gemcitabine or oxaliplatin\/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review. Cancer Med. 3, 1502\u20131511 (2014).","journal-title":"Cancer Med."},{"key":"75102_CR6","doi-asserted-by":"publisher","first-page":"e0266707","DOI":"10.1371\/journal.pone.0266707","volume":"17","author":"M Ishii","year":"2022","unstructured":"Ishii, M., Itano, O., Morinaga, J., Shirakawa, H. & Itano, S. Potential efficacy of hepatic arterial infusion chemotherapy using gemcitabine, cisplatin, and 5-fluorouracil for intrahepatic cholangiocarcinoma. PLoS One. 17, e0266707 (2022).","journal-title":"PLoS One"},{"key":"75102_CR7","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1186\/s12885-020-07365-4","volume":"20","author":"M Ueno","year":"2020","unstructured":"Ueno, M. et al. Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: Primary analysis results. BMC Cancer. 20, 1105 (2020).","journal-title":"BMC Cancer"},{"key":"75102_CR8","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1080\/07853890.2022.2048416","volume":"54","author":"M Deng","year":"2022","unstructured":"Deng, M. et al. Real-world outcomes of patients with advanced intrahepatic cholangiocarcinoma treated with programmed cell death protein-1-targeted immunotherapy. Ann. Med. 54, 803\u2013811 (2022).","journal-title":"Ann. Med."},{"key":"75102_CR9","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1093\/annonc\/mdz402","volume":"30","author":"C Morizane","year":"2019","unstructured":"Morizane, C. et al. Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced\/recurrent biliary tract cancer: The FUGA-BT (JCOG1113) randomized phase III clinical trial. Ann. Oncol. 30, 1950\u20131958 (2019).","journal-title":"Ann. Oncol."},{"key":"75102_CR10","first-page":"176","volume":"10","author":"WD Ensminger","year":"1983","unstructured":"Ensminger, W. D. & Gyves, J. W. Clinical pharmacology of hepatic arterial chemotherapy. Semin Oncol. 10, 176\u2013182 (1983).","journal-title":"Semin Oncol."},{"key":"75102_CR11","first-page":"3784","volume":"38","author":"WD Ensminger","year":"1978","unstructured":"Ensminger, W. D. et al. A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2\u2019-deoxyuridine and 5-fluorouracil. Cancer Res. 38, 3784\u20133792 (1978).","journal-title":"Cancer Res."},{"key":"75102_CR12","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1148\/radiol.2016160572","volume":"283","author":"X Wang","year":"2017","unstructured":"Wang, X. et al. Phase II study of hepatic arterial infusion chemotherapy with oxaliplatin and 5-fluorouracil for advanced perihilar cholangiocarcinoma. Radiology. 283, 580\u2013589 (2017).","journal-title":"Radiology"},{"key":"75102_CR13","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1001\/jamaoncol.2019.3718","volume":"6","author":"A Cercek","year":"2020","unstructured":"Cercek, A. et al. Assessment of hepatic arterial infusion of Floxuridine in Combination with systemic gemcitabine and oxaliplatin in patients with Unresectable Intrahepatic Cholangiocarcinoma: A phase 2 clinical trial. JAMA Oncol. 6, 60\u201367 (2020).","journal-title":"JAMA Oncol."},{"key":"75102_CR14","doi-asserted-by":"crossref","unstructured":"Tohyama, O. et al. Antitumor activity of lenvatinib (e7080): An angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res 638747 (2014). (2014).","DOI":"10.1155\/2014\/638747"},{"key":"75102_CR15","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa, G. K. et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: A multicentre, open-label, phase 2 study. Lancet Oncol. 21, 671\u2013684 (2020).","journal-title":"Lancet Oncol."},{"key":"75102_CR16","doi-asserted-by":"crossref","unstructured":"Oh, D. Y. et al. A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1. American Society of Clinical Oncology. (2022).","DOI":"10.1200\/JCO.2022.40.4_suppl.378"},{"key":"75102_CR17","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41392-023-01317-7","volume":"8","author":"GM Shi","year":"2023","unstructured":"Shi, G. M. et al. Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: A single-center, single-arm, phase 2 study. Signal. Transduct. Target. Ther. 8, 106 (2023).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"75102_CR18","first-page":"3455","volume":"12","author":"T Zhang","year":"2022","unstructured":"Zhang, T. et al. Different interventional time of hepatic arterial infusion with PD-1 inhibitor for advanced biliary tract cancer: A multicenter retrospective study. Am. J. Cancer Res. 12, 3455\u20133463 (2022).","journal-title":"Am. J. Cancer Res."},{"key":"75102_CR19","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1002\/hep.31840","volume":"74","author":"JW Cheu","year":"2021","unstructured":"Cheu, J. W. & Wong, C. C. Mechanistic rationales guiding combination hepatocellular carcinoma therapies involving immune checkpoint inhibitors. Hepatology. 74, 2264\u20132276 (2021).","journal-title":"Hepatology"},{"key":"75102_CR20","doi-asserted-by":"publisher","first-page":"6469","DOI":"10.3748\/wjg.v22.i28.6469","volume":"22","author":"E Moreno-Cubero","year":"2016","unstructured":"Moreno-Cubero, E. & Larrubia, J. R. Specific CD8(+) T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis. World J. Gastroenterol. 22, 6469\u20136483 (2016).","journal-title":"World J. Gastroenterol."},{"key":"75102_CR21","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer. 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"75102_CR22","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.jhep.2019.09.026","volume":"72","author":"JM Llovet","year":"2020","unstructured":"Llovet, J. M. & Lencioni, R. mRECIST for HCC: performance and novel refinements. J. Hepatol. 72, 288\u2013306 (2020).","journal-title":"J. Hepatol."},{"key":"75102_CR23","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","volume":"112","author":"A Freites-Martinez","year":"2021","unstructured":"Freites-Martinez, A., Santana, N., Arias-Santiago, S. & Viera, A. Using the common terminology criteria for adverse events (CTCAE - version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr (Engl Ed). 112, 90\u201392 (2021).","journal-title":"Actas Dermosifiliogr (Engl Ed)"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-75102-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-75102-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-75102-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T06:12:17Z","timestamp":1729836737000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-75102-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,14]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["75102"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-75102-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,14]]},"assertion":[{"value":"5 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Informed consent was obtained from all patients for being included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (Zhongshan People\u2019s Hospital) and with the Helsinki Declaration of 1975, as revised in 2008 (5).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}}],"article-number":"23961"}}